--- title: "MoonLake Immunotherapeutics (MLTX) news: class action" url: "https://aibio.space/companies/moonlake-immunotherapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "MLTX class action news: MoonLake faces securities class action over sonelokimab; motion to dismiss pending." --- MLTX MoonLake Immunotherapeutics NASDAQ · Switzerland # MoonLake Immunotherapeutics (MLTX) news MLTX class action news Legal · 2026-08-10 ## [MoonLake faces securities class action over sonelokimab; motion to dismiss pending](https://aibio.space/news/moonlake-faces-securities-class-action-sonelokimab-motion-dismiss/) The Peters suit names MoonLake and its chief executive, chief financial and chief scientific officers. The class period runs March 10, 2024 through September 29, 2025. ## Latest MoonLake Immunotherapeutics news 1. 2026-02-23 Debt Financing [MoonLake amends Hercules loan, draws $25.0 million and keeps up to $400.0 million in later tranches](https://aibio.space/news/moonlake-amends-hercules-loan-draws-25-0-million-keeps-up-400-0/) MoonLake drew $25.0 million under a Hercules loan totaling $500.0 million across six tranches. Most of the tranches still to come depend on Phase 3 results and FDA action for its lead drug, sonelokimab, and the company's 81% response figure comes from 26 patients with no comparison arm reported. 2. 2025-04-03 Debt Financing [MoonLake draws $75.0 million of Hercules Capital loan facility of up to $500.0 million](https://aibio.space/news/moonlake-draws-75-0-million-hercules-capital-loan-facility-up-500-0/) MoonLake's subsidiary, MoonLake Immunotherapeutics AG, borrowed the first tranche on March 31, 2025. Most further tranches depend on trial and FDA milestones, and the facility matures April 1, 2030. ## MoonLake Immunotherapeutics at a glance - **Ticker**: MLTX - **Listing**: NASDAQ - **Country**: Switzerland - **Cash, Jun 30, 2026**: $537.0 million ### Related companies - [Idorsia](https://aibio.space/companies/idorsia/) SIX: IDIA - [Santhera Pharmaceuticals Holding](https://aibio.space/companies/santhera-pharmaceuticals/) SIX: SANN - [ADC Therapeutics SA](https://aibio.space/companies/adc-therapeutics/) NYSE: ADCT - [Bachem Holding](https://aibio.space/companies/bachem/) SIX: BANB - [Addex Therapeutics](https://aibio.space/companies/addex-therapeutics/) SIX: ADXN - [Sandoz Group](https://aibio.space/companies/sandoz/) SIX: SDZ - [Siegfried Holding](https://aibio.space/companies/siegfried/) SIX: SFZN - [AC Immune SA](https://aibio.space/companies/ac-immune/) NASDAQ: ACIU ### Also on NASDAQ - [TriSalus Life Sciences](https://aibio.space/companies/trisalus-life-sciences/) TLSI - [Axogen](https://aibio.space/companies/axogen/) AXGN - [Lisata Therapeutics](https://aibio.space/companies/lisata-therapeutics/) LSTA - [Bon Natural Life](https://aibio.space/companies/bon-natural-life/) BON - [iSpecimen](https://aibio.space/companies/ispecimen/) ISPC - [Cingulate](https://aibio.space/companies/cingulate/) CING ## What MoonLake Immunotherapeutics does MoonLake Immunotherapeutics is a clinical stage biotechnology company developing therapies for inflammatory skin and joint diseases. It is a single asset company focused on SLK, a tri-specific IL-17A and IL-17F inhibiting Nanobody exclusively licensed from MHKDG. SLK was discovered by Ablynx N.V., a Sanofi company, and previously studied by MHKDG and Avillion LLP under a 2017 co-development agreement. Its target diseases are hidradenitis suppurativa (HS), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), palmoplantar pustulosis (PPP) and psoriasis. In September 2025 the company reported primary endpoint data from the Phase 3 VELA-1 and VELA-2 trials in HS, where patients treated with SLK showed statistically significant improvement across all primary and key secondary endpoints. Enrollment in the Phase 3 IZAR-1 trial in PsA was completed in February 2026. A Phase 2 trial in axSpA reported that 81% of patients achieved an ASAS40 response at week 12. In a Phase 2 trial in PPP, the mean percent change from baseline in the PPPASI was 64% at week 16, and the FDA granted Fast Track designation for SLK in moderate-to-severe PPP. | Product or program | What it is | Stage | |---|---|---| | SLK in hidradenitis suppurativa | IL-17A/F inhibiting Nanobody for moderate-to-severe HS | Phase 3 (VELA-1, VELA-2) | | SLK in psoriatic arthritis | IL-17A/F inhibiting Nanobody for active PsA | Phase 3 (IZAR-1, IZAR-2) | | SLK in axial spondyloarthritis | IL-17A/F inhibiting Nanobody for axSpA | Phase 2 (S-OLARIS) | | SLK in palmoplantar pustulosis | IL-17A/F inhibiting Nanobody for PPP | Phase 2 (LEDA); Fast Track designation | Summarised from the company's [10-K filed Feb 25, 2026](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000002/mnlk-20251231.htm). ## MoonLake Immunotherapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$202.9 million](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000002/) | [$112.8 million](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000002/) | | Net income (loss) | [-$227.3 million](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000002/) | [-$118.9 million](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000002/) | | Cash from operations | [-$196.0 million](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000002/) | [-$116.6 million](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000002/) | | Cash and equivalents | [$334.5 million](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000010/) | [$180.4 million](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000002/) | | Short-term investments | [$59.5 million](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000010/) | [$267.6 million](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000002/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $477.9 million, plus short-term investments of $59.1 million, $537.0 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about MoonLake Immunotherapeutics Is there a class action against MoonLake Immunotherapeutics? Our latest story on this, dated Aug 10, 2026: "MoonLake faces securities class action over sonelokimab; motion to dismiss pending". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/moonlake-faces-securities-class-action-sonelokimab-motion-dismiss/). What is the ticker symbol of MoonLake Immunotherapeutics? MoonLake Immunotherapeutics trades under the ticker MLTX on NASDAQ. Where is MoonLake Immunotherapeutics listed? MoonLake Immunotherapeutics is listed on NASDAQ. What is the SEC CIK of MoonLake Immunotherapeutics? The SEC Central Index Key (CIK) for MoonLake Immunotherapeutics is 1821586. Its filings are on SEC EDGAR. How many shares does MoonLake Immunotherapeutics have outstanding? 85,106,685 shares as of 2026-08-01, per the cover page of its 10-Q filed 2026-08-10. Which country or territory is MoonLake Immunotherapeutics listed under? Our directory records MoonLake Immunotherapeutics under Switzerland. What does MoonLake Immunotherapeutics do? Our directory classifies MoonLake Immunotherapeutics as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of MoonLake Immunotherapeutics? The ISIN recorded for MoonLake Immunotherapeutics is KY61559X1045. Does aibio.space cover MoonLake Immunotherapeutics? aibio.space lists MoonLake Immunotherapeutics among 2,820 public biotech companies and publishes its news here as stories appear. Where is MoonLake Immunotherapeutics incorporated? SEC records list its state or country of incorporation as E9. What does MoonLake Immunotherapeutics develop? MoonLake Immunotherapeutics is a clinical stage biotechnology company developing therapies for inflammatory skin and joint diseases. It is a single asset company focused on SLK, a tri-specific IL-17A and IL-17F inhibiting Nanobody exclusively licensed from MHKDG. What is SLK in hidradenitis suppurativa from MoonLake Immunotherapeutics? SLK in hidradenitis suppurativa: IL-17A/F inhibiting Nanobody for moderate-to-severe HS Stage: Phase 3 (VELA-1, VELA-2). What is SLK in psoriatic arthritis from MoonLake Immunotherapeutics? SLK in psoriatic arthritis: IL-17A/F inhibiting Nanobody for active PsA Stage: Phase 3 (IZAR-1, IZAR-2). Is MoonLake Immunotherapeutics profitable? MoonLake Immunotherapeutics reported a net loss of $227.3 million for the fiscal year ended Dec 31, 2025, and used $196.0 million of cash in operations, per its annual report to the SEC. How much does MoonLake Immunotherapeutics spend on research and development? $202.9 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: MoonLake Immunotherapeutics Members talk about MoonLake Immunotherapeutics (MLTX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at MoonLake Immunotherapeutics, newest first. Each line links the filing it comes from. 1. 2026-07-15 Financings Reported a financing. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1821586/000121390026078031/ea0298054-8k_moonlake.htm) 2. 2026-06-22 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1821586/000121390026070709/ea0295422-424b5_moonlake.htm) 3. 2026-02-25 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000002/mnlk-20251231.htm) 4. 2026-02-23 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.02,2.03,5.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1821586/000121390026018967/ea027791001ex99-1_moonlake.htm) 5. 2025-11-05 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1821586/000121390025106722/ea0263850-424b5_moonlake.htm) 6. 2025-02-26 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1821586/000182158625000006/mnlk-20241231.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:MLTX on TradingView](https://www.tradingview.com/symbols/NASDAQ-MLTX/). ## SEC filings and registration - **SEC name**: MoonLake Immunotherapeutics - **CIK**: 1821586 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: MLTX (Nasdaq) - **State or country of incorporation**: E9 - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: DORFSTRASSE 29, ZUG, Switzerland, 6300 - **Phone**: 41 41 510 8022 - **Shares outstanding**: 85,106,685 as of 2026-08-01 (10-Q filed 2026-08-10) - **Former names**: Helix Acquisition Corp ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1821586/000121390026105240/ea0307097-8k_moonlake.htm) filed 2026-09-30 - [10-Q](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000010/mnlk-20260630.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1821586/000121390026086939/ea0301191-8k_moonlake.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1821586/000121390026078031/ea0298054-8k_moonlake.htm) filed 2026-07-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1821586/000121390026071721/ea0295766-8k_moonlake.htm) filed 2026-06-25 - [424B5](https://www.sec.gov/Archives/edgar/data/1821586/000121390026071586/ea0295767-424b5_moonlake.htm) filed 2026-06-24 - [424B5](https://www.sec.gov/Archives/edgar/data/1821586/000121390026070709/ea0295422-424b5_moonlake.htm) filed 2026-06-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1821586/000121390026070362/ea0295399-8k_moonlake.htm) filed 2026-06-22 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001821586), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details MoonLake Immunotherapeutics is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MLTX, recorded under Switzerland. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: MoonLake Immunotherapeutics - **Ticker**: MLTX - **Listing**: NASDAQ - **Country or territory**: Switzerland - **Business scope**: Pharmaceuticals: Major - **ISIN**: KY61559X1045 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-MLTX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/moonlake-immunotherapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "MoonLake Immunotherapeutics (MLTX) news: class action", 2026-10-31, https://aibio.space/companies/moonlake-immunotherapeutics/